<?xml version='1.0' encoding='utf-8'?>
<document id="20092221"><sentence text="Is tapentadol an advance on tramadol?"><entity charOffset="3-13" id="DDI-PubMed.20092221.s1.e0" text="tapentadol" /><entity charOffset="28-36" id="DDI-PubMed.20092221.s1.e1" text="tramadol" /><pair ddi="false" e1="DDI-PubMed.20092221.s1.e0" e2="DDI-PubMed.20092221.s1.e0" /><pair ddi="false" e1="DDI-PubMed.20092221.s1.e0" e2="DDI-PubMed.20092221.s1.e1" /></sentence><sentence text="To review the pharmacodynamics, pharmacokinetics, clinical efficacy, tolerability, dosing, and administration of tapentadol, a combination mu-opioid-receptor agonist and monoamine-reuptake inhibitor, and compare it with tramadol, the first drug in this class"><entity charOffset="113-123" id="DDI-PubMed.20092221.s2.e0" text="tapentadol" /><entity charOffset="170-179" id="DDI-PubMed.20092221.s2.e1" text="monoamine" /><entity charOffset="220-228" id="DDI-PubMed.20092221.s2.e2" text="tramadol" /><pair ddi="false" e1="DDI-PubMed.20092221.s2.e0" e2="DDI-PubMed.20092221.s2.e0" /><pair ddi="false" e1="DDI-PubMed.20092221.s2.e0" e2="DDI-PubMed.20092221.s2.e1" /><pair ddi="false" e1="DDI-PubMed.20092221.s2.e0" e2="DDI-PubMed.20092221.s2.e2" /><pair ddi="false" e1="DDI-PubMed.20092221.s2.e1" e2="DDI-PubMed.20092221.s2.e1" /><pair ddi="false" e1="DDI-PubMed.20092221.s2.e1" e2="DDI-PubMed.20092221.s2.e2" /></sentence><sentence text="" /><sentence text="MEDLINE/PUBMED and EMBASE searches (1986 through March 2009) were conducted to identify pertinent English-language papers" /><sentence text=" In addition, meeting abstracts from multiple pain specialty organizations were searched (2000 through 2008)" /><sentence text="" /><sentence text="All papers/abstracts evaluating any aspect of tapentadol"><entity charOffset="46-56" id="DDI-PubMed.20092221.s7.e0" text="tapentadol" /></sentence><sentence text="" /><sentence text="Oral tapentadol hydrochloride (HCl) is the second combination mu-opioid-receptor agonist and monoamine-reuptake inhibitor to be approved by the Food and Drug Administration (approved for treatment of moderate-to-severe acute pain in adults)"><entity charOffset="5-29" id="DDI-PubMed.20092221.s9.e0" text="tapentadol hydrochloride" /><entity charOffset="31-34" id="DDI-PubMed.20092221.s9.e1" text="HCl" /><entity charOffset="93-102" id="DDI-PubMed.20092221.s9.e2" text="monoamine" /><pair ddi="false" e1="DDI-PubMed.20092221.s9.e0" e2="DDI-PubMed.20092221.s9.e0" /><pair ddi="false" e1="DDI-PubMed.20092221.s9.e0" e2="DDI-PubMed.20092221.s9.e1" /><pair ddi="false" e1="DDI-PubMed.20092221.s9.e0" e2="DDI-PubMed.20092221.s9.e2" /><pair ddi="false" e1="DDI-PubMed.20092221.s9.e1" e2="DDI-PubMed.20092221.s9.e1" /><pair ddi="false" e1="DDI-PubMed.20092221.s9.e1" e2="DDI-PubMed.20092221.s9.e2" /></sentence><sentence text=" It was active in a wide variety of pain states in animals and humans" /><sentence text=" It behaved in a similar fashion to morphine and hydromorphone in animal and human models of physical/psychological dependence"><entity charOffset="36-44" id="DDI-PubMed.20092221.s11.e0" text="morphine" /><entity charOffset="49-62" id="DDI-PubMed.20092221.s11.e1" text="hydromorphone" /><pair ddi="false" e1="DDI-PubMed.20092221.s11.e0" e2="DDI-PubMed.20092221.s11.e0" /><pair ddi="false" e1="DDI-PubMed.20092221.s11.e0" e2="DDI-PubMed.20092221.s11.e1" /></sentence><sentence text=" Oral tapentadol HCI is administered in doses of 50 to 100 mg every four to six hours (dose and dosing interval being selected on the basis of pain intensity)"><entity charOffset="6-20" id="DDI-PubMed.20092221.s12.e0" text="tapentadol HCI" /></sentence><sentence text=" No specific recommendations have been made for elders" /><sentence text="" /><sentence text="Tapentadol overcomes some of the liabilities of tramadol"><entity charOffset="0-10" id="DDI-PubMed.20092221.s15.e0" text="Tapentadol" /><entity charOffset="48-56" id="DDI-PubMed.20092221.s15.e1" text="tramadol" /><pair ddi="false" e1="DDI-PubMed.20092221.s15.e0" e2="DDI-PubMed.20092221.s15.e0" /><pair ddi="false" e1="DDI-PubMed.20092221.s15.e0" e2="DDI-PubMed.20092221.s15.e1" /></sentence><sentence text=" However, it still has some liabilities: its potential to contribute to/precipitate serotonin syndrome and anticholinergic/5-HT3 antagonist effects and to induce physical/psychological dependence (similar to schedule II opioids)"><entity charOffset="84-93" id="DDI-PubMed.20092221.s16.e0" text="serotonin" /></sentence><sentence text=" There is also a dearth of information in terms of efficacy/tolerability in chronic pain states, clinical data in frail elders, and details of drug-drug interaction potential vis-Ã -vis glucuronidation and quantitation of the risk of serotonin syndrome"><entity charOffset="233-242" id="DDI-PubMed.20092221.s17.e0" text="serotonin" /></sentence><sentence text="" /></document>